Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:

Adeeb A. Bulkhi, MD, MSc; Ahmad A. Mirza, MBBS, MSc; Abdullah J. Aburiziza, MD, ABP; Osama A. Marglani, MD, FRCSC

World Allergy Organization Journal (Mar 2022)

Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:

Adeeb A. Bulkhi, MD, MSc,
Ahmad A. Mirza, MBBS, MSc,
Abdullah J. Aburiziza, MD, ABP,
Osama A. Marglani, MD, FRCSC

Affiliations

Adeeb A. Bulkhi, MD, MSc: Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, Fl, USA; Department of Allergy and Immunology, King Abdullah Medical City, Makkah, Saudi Arabia
Ahmad A. Mirza, MBBS, MSc: Department of Otolaryngology–Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Otolaryngology–Head and Neck Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Corresponding author. Department of Otolaryngology–Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, P.O. Box 80200, Jeddah, 21589, Saudi Arabia.
Abdullah J. Aburiziza, MD, ABP: Department of Pediatrics, Umm Al-Qura University (UQU), Makkah, Saudi Arabia
Osama A. Marglani, MD, FRCSC: Department of Ophthalmology, and Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; Department of Surgery, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia

Journal volume & issue: Vol. 15, no. 3
p. 100638

Abstract

Read online

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.

Published in World Allergy Organization Journal

ISSN: 1939-4551 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://www.sciencedirect.com/journal/world-allergy-organization-journal

About the journal

Abstract

Keywords